Literature DB >> 22045476

Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.

Daphne D D Rietbergen1, Bernies van der Hiel, Wouter Vogel, Marcel P M Stokkel.   

Abstract

SUMMARY: Fluorine-18-methyl-choline (F18-choline) PET/computed tomography (CT) is routinely performed in our hospital for patients with significantly increased or rapidly increasing prostate-specific antigen (PSA) levels to detect and localize recurrent prostate carcinoma. We observed uptake of this PET tracer in mediastinal lymph nodes in a significant number of patients. The aim of this study was to assess the frequency of this finding and to determine whether it is correlated with tumour and nontumour-related aspects.
MATERIALS AND METHODS: A total of 48 consecutive men (mean age: 65.6 years; range: 50-79 years, standard deviation: 7.1) with histopathologically proven prostate cancer were referred for F18-choline PET/CT imaging for restaging from March 2009 to October 2010. All patients had a suspicion of tumour recurrence because of an increased PSA or a rapidly increasing PSA. All studies were reviewed, and the results were correlated with general data such as age; smoking; chronic obstructive pulmonary disease; tumor, lymph nodes and distant metastases stage; Gleason Score and PSA level; with a maximum interval of 3 months between serum PSA and the PET/CT scan.
RESULTS: In 27 patients (56.3%), F18-choline PET/CT showed positive lymph nodes in the mediastinum (mean standardized uptake values: 3.75; range: 1.7-13.8, standard deviation: 2.4). No histological biopsy was carried out in F18-choline-positive lymph nodes, but in none of the patients was mediastinal recurrence or pulmonary infection observed during a 6-month follow-up. Only one patient had histologically proven pulmonary metastasis. No significant relationship was observed between mediastinal F18-choline lymph node uptake and serum PSA level (P=0.785), initial T stage (P=0.555), N stage (P=0.548), M stage (P=0.426), smoking (P=0.537), chronic obstructive pulmonary disease (P=0.115) or the presence of tumour recurrence on F18-choline PET/CT.
CONCLUSION: Mediastinal lymph node uptake of F18 choline is frequently observed, without any significant relationship with tumour characteristics. Therefore, interpretation of positive mediastinal lymph node uptake should be done carefully.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045476     DOI: 10.1097/MNM.0b013e32834b76fa

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  About the specificity of radiotracers for prostate cancer.

Authors:  Michael Soussan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-07       Impact factor: 9.236

Review 2.  18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.

Authors:  Claudia Brogsitter; Klaus Zöphel; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

3.  Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.

Authors:  Sandi A Kwee; Marc N Coel; John Lim
Journal:  Ann Nucl Med       Date:  2012-05-02       Impact factor: 2.668

4.  A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems.

Authors:  Daniela E Oprea-Lager; Maqsood Yaqub; Indra C Pieters; Rinze Reinhard; Reindert J A van Moorselaar; Alfons J M van den Eertwegh; Otto S Hoekstra; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

5.  (11)C-Choline and FDG PET/CT Imaging of Primary Cholangiocarcinoma: A Comparative Analysis.

Authors:  Chanisa Chotipanich; Chetsadaporn Promteangtrong; Anchisa Kunawudhi; Rawisak Chanwat; Thaniya Sricharunrat; Savitree Suratako; Paramest Wongsa
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

6.  Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [18F]fluoromethyl-(1,2-2H4)-choline.

Authors:  Suraiya Dubash; Marianna Inglese; Francesco Mauri; Kasia Kozlowski; Pritesh Trivedi; Mubarik Arshad; Amarnath Challapalli; Tara Barwick; Adil Al-Nahhas; Rex Stanbridge; Conrad Lewanski; Matthew Berry; Frances Bowen; Eric O Aboagye
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.